CTXR
Citius Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.55
+0.01 (+1.19%)
Current Price
| Previous Close | $0.54 |
| Open | $0.54 |
| Day High | $0.57 |
| Day Low | $0.54 |
| Volume | 242,919 |
Stock Information
| Shares Outstanding | 27.45M |
| Total Debt | $808K |
| Cash Equivalents | $4.59M |
| Revenue | $5.61M |
| Net Income | $-46.20M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $15.00M |
| EPS (TTM) | $-2.11 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $18.76M |
| Sales | $5.61M |
| Income | $-46.20M |
| Book/sh | $2.75 |
| Cash/sh | $0.17 |
| Employees | 23 |
Financial Ratios
| Quick Ratio | 0.10 |
| Current Ratio | 0.58 |
| Debt/Eq | 1.17 |
Returns & Margins
| ROA | -27.63% |
| ROE | -83.60% |
| Gross Margin | 80.07% |
| Operating Margin | -1827.78% |
Ownership
| Insider Ownership | 1.80% |
| Institutional Ownership | 3.63% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.67 |
| P/S | 2.67 |
| P/B | 0.20 |
Analyst Data
| Recommendation | none |
| Target Price | $4.00 |
Technical Indicators
| SMA20 | $0.60 |
| SMA50 | $0.68 |
| SMA200 | $0.96 |
| RSI | 27.57 |
| ATR | 0.0427 |
| Shares Float | 26.96M |
| Short Float | 18.35% |
| Short Ratio | 5.56 |
| Volatility | 0.98 |
| Rel Volume | 0.62 |
Performance History
| Week | -4.71% |
| Month | -1.44% |
| Quarter | -32.76% |
| 6 Months | -50.36% |
| YTD | -35.61% |
| Year | -35.99% |
| 3 Years | -98.27% |
| 5 Years | -99.16% |
| 10 Years | -99.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.55 | 256,900 |
| 2026-06-17 | $0.54 | 191,900 |
| 2026-06-16 | $0.54 | 203,100 |
| 2026-06-15 | $0.54 | 289,300 |
| 2026-06-12 | $0.54 | 420,000 |
| 2026-06-11 | $0.57 | 106,500 |
| 2026-06-10 | $0.55 | 285,900 |
| 2026-06-09 | $0.56 | 411,600 |
| 2026-06-08 | $0.59 | 472,600 |
| 2026-06-05 | $0.56 | 261,800 |
| 2026-06-04 | $0.59 | 177,200 |
| 2026-06-03 | $0.58 | 303,200 |
| 2026-06-02 | $0.60 | 450,300 |
| 2026-06-01 | $0.63 | 493,300 |
| 2026-05-29 | $0.65 | 380,100 |
| 2026-05-28 | $0.65 | 1,118,200 |
| 2026-05-27 | $0.69 | 510,800 |
| 2026-05-26 | $0.70 | 541,000 |
| 2026-05-22 | $0.70 | 433,900 |
| 2026-05-21 | $0.67 | 995,800 |
| 2026-05-20 | $0.58 | 917,000 |
| 2026-05-19 | $0.55 | 786,800 |
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
đ° Latest News
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
Insider Monkey âĸ 2026-05-24T11:49:30Z
Citius Pharmaceuticals Secures $5M Through Equity Offering
InvestorsHub âĸ 2026-04-24T14:48:07Z
We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon
Simply Wall St. âĸ 2026-04-21T17:09:48Z
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR
Insider Monkey âĸ 2026-03-06T20:00:27Z
Citius Oncology and Uniphar sign European distribution deal for Lymphir
Pharmaceutical Technology âĸ 2026-02-12T11:55:29Z
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Is Expected To Breakeven In The Near Future
Simply Wall St. âĸ 2025-11-12T16:21:05Z
Citius Oncology, Inc. (NASDAQ:CTOR) stock most popular amongst public companies who own 79%, while individual investors hold 14%
Simply Wall St. âĸ 2025-09-26T11:29:05Z
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR
Insider Monkey âĸ 2025-07-06T08:01:20Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $267,782 | - | - | $0 |
| Total Expenses | $38,525,608 | $41,995,681 | $36,732,018 | $33,316,045 |
| Net Non Operating Interest Income Expense | $-157,701 | $758,000 | $1,179,417 | $251,399 |
| Interest Expense Non Operating | $267,782 | - | - | $0 |
| Operating Expense | $38,525,608 | $41,995,681 | $36,732,018 | $33,316,045 |
| General And Administrative Expense | $29,369,134 | $30,089,080 | $21,912,289 | $15,660,563 |
| Other Income Expense | - | $2,387,842 | $3,585,689 | - |
| Other Non Operating Income Expenses | - | $2,387,842 | $3,585,689 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-37,433,911 | $-39,138,839 | $-32,542,912 | $-33,640,646 |
| Net Interest Income | $-157,701 | $758,000 | $1,179,417 | $251,399 |
| Interest Income | $110,081 | $758,000 | $1,179,417 | $251,399 |
| Normalized Income | $-37,433,911 | $-39,138,839 | $-32,542,912 | $-33,640,646 |
| Net Income From Continuing And Discontinued Operation | $-37,433,911 | $-39,138,839 | $-32,542,912 | $-33,640,646 |
| Total Operating Income As Reported | $-38,525,608 | $-41,995,681 | $-36,732,018 | $-33,316,045 |
| Net Income Common Stockholders | $-37,433,911 | $-40,186,151 | $-33,694,120 | $-33,640,646 |
| Net Income | $-37,433,911 | $-39,138,839 | $-32,542,912 | $-33,640,646 |
| Net Income Including Noncontrolling Interests | $-39,740,269 | $-39,425,839 | $-32,542,912 | $-33,640,646 |
| Net Income Continuous Operations | $-39,740,269 | $-39,425,839 | $-32,542,912 | $-33,640,646 |
| Pretax Income | $-38,683,309 | $-38,849,839 | $-31,966,912 | $-33,064,646 |
| Interest Income Non Operating | $110,081 | $758,000 | $1,179,417 | $251,399 |
| Operating Income | $-38,525,608 | $-41,995,681 | $-36,732,018 | $-33,316,045 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-3.38 | $-5.97 | $-5.57 | $-5.75 |
| Basic EPS | $-3.38 | $-5.97 | $-5.57 | $-5.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-38,201,277 | $-41,786,070 | $-36,537,702 | $-33,136,368 |
| Reconciled Depreciation | $214,250 | $209,611 | $194,316 | $179,677 |
| EBITDA (Bullshit earnings) | $-38,201,277 | $-41,786,070 | $-36,537,702 | $-33,136,368 |
| EBIT | $-38,415,527 | $-41,995,681 | $-36,732,018 | $-33,316,045 |
| Diluted Average Shares | $11,065,225 | $6,726,999 | $6,051,789 | $5,843,295 |
| Basic Average Shares | $11,065,225 | $6,726,999 | $6,051,789 | $5,843,295 |
| Diluted NI Availto Com Stockholders | $-37,433,911 | $-40,186,151 | $-33,694,120 | $-33,640,646 |
| Otherunder Preferred Stock Dividend | $0 | $1,047,312 | $1,151,208 | $0 |
| Minority Interests | $2,306,358 | $287,000 | $0 | - |
| Tax Provision | $1,056,960 | $576,000 | $576,000 | $576,000 |
| Research And Development | $9,156,474 | $11,906,601 | $14,819,729 | $17,655,482 |
| Selling General And Administration | $29,369,134 | $30,089,080 | $21,912,289 | $15,660,563 |
| Other Gand A | $18,532,843 | $18,249,402 | $15,295,584 | $11,754,609 |
| Salaries And Wages | $10,836,291 | $11,839,678 | $6,616,705 | $3,905,954 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-34,596,618 | $-32,069,346 | $22,084,312 | $34,079,069 |
| Total Assets | $130,938,025 | $116,651,751 | $103,611,150 | $113,999,302 |
| Total Non Current Assets | $103,003,552 | $102,431,105 | $69,240,716 | $69,435,032 |
| Non Current Prepaid Assets | $38,062 | $38,062 | $38,062 | $38,062 |
| Goodwill And Other Intangible Assets | $102,146,796 | $102,146,796 | $68,746,796 | $68,746,796 |
| Other Intangible Assets | $92,800,000 | $92,800,000 | $59,400,000 | $59,400,000 |
| Current Assets | $27,934,473 | $14,220,646 | $34,370,434 | $44,564,270 |
| Prepaid Assets | $1,395,490 | $2,700,000 | $7,889,506 | $2,852,580 |
| Inventory | $22,286,693 | $8,268,766 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $4,252,290 | $3,251,880 | $26,480,928 | $41,711,690 |
| Cash And Cash Equivalents | $4,252,290 | $3,251,880 | $26,480,928 | $41,711,690 |
| Debt | ||||
| Total Debt | $1,813,273 | $262,865 | $481,245 | $678,234 |
| Long Term Debt And Capital Lease Obligation | $724,925 | $21,318 | $262,865 | $481,245 |
| Current Debt And Capital Lease Obligation | $1,088,348 | $241,547 | $218,380 | $196,989 |
| Current Debt | $1,000,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,410,425 | $42,549,921 | $12,179,662 | $10,573,057 |
| Total Non Current Liabilities Net Minority Interest | $8,495,685 | $6,735,118 | $6,400,665 | $6,043,045 |
| Non Current Deferred Liabilities | $7,770,760 | $6,713,800 | $6,137,800 | $5,561,800 |
| Non Current Deferred Taxes Liabilities | $7,770,760 | $6,713,800 | $6,137,800 | $5,561,800 |
| Current Liabilities | $44,914,740 | $35,814,803 | $5,778,997 | $4,530,012 |
| Current Notes Payable | $1,000,000 | - | - | - |
| Payables And Accrued Expenses | $40,533,945 | $33,344,238 | $3,403,634 | $2,570,772 |
| Payables | $36,343,692 | $33,327,211 | $2,927,334 | $1,165,378 |
| Other Payable | $22,650,000 | $28,400,000 | - | - |
| Accounts Payable | $13,693,692 | $4,927,211 | $2,927,334 | $1,165,378 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $67,550,178 | $70,077,450 | $90,831,108 | $102,825,865 |
| Total Equity Gross Minority Interest | $77,527,600 | $74,101,830 | $91,431,488 | $103,426,245 |
| Stockholders Equity | $67,550,178 | $70,077,450 | $90,831,108 | $102,825,865 |
| Retained Earnings | $-238,804,129 | $-201,370,218 | $-162,231,379 | $-129,688,467 |
| Other | ||||
| Ordinary Shares Number | $18,067,744 | $7,247,243 | $6,354,311 | $5,848,445 |
| Share Issued | $18,067,744 | $7,247,243 | $6,354,311 | $5,848,445 |
| Tangible Book Value | $-34,596,618 | $-32,069,346 | $22,084,312 | $34,079,069 |
| Invested Capital | $68,550,178 | $70,077,450 | $90,831,108 | $102,825,865 |
| Working Capital | $-16,980,267 | $-21,594,157 | $28,591,437 | $40,034,258 |
| Capital Lease Obligations | $813,273 | $262,865 | $481,245 | $678,234 |
| Total Capitalization | $67,550,178 | $70,077,450 | $90,831,108 | $102,825,865 |
| Minority Interest | $9,977,422 | $4,024,380 | $600,380 | $600,380 |
| Additional Paid In Capital | $306,336,239 | $271,440,421 | $253,056,133 | $232,368,121 |
| Capital Stock | $18,068 | $7,247 | $6,354 | $146,211 |
| Common Stock | $18,068 | $7,247 | $6,354 | $146,211 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $724,925 | $21,318 | $262,865 | $481,245 |
| Current Capital Lease Obligation | $88,348 | $241,547 | $218,380 | $196,989 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,292,447 | $2,229,018 | $2,156,983 | $1,762,251 |
| Current Accrued Expenses | $4,190,253 | $17,027 | $476,300 | $1,405,394 |
| Goodwill | $9,346,796 | $9,346,796 | $9,346,796 | $9,346,796 |
| Net PPE | $818,694 | $246,247 | $455,858 | $650,174 |
| Gross PPE | $818,694 | $246,247 | $455,858 | $650,174 |
| Other Properties | $818,694 | $246,247 | $455,858 | $650,174 |
| Finished Goods | $10,577,876 | $6,134,895 | - | - |
| Work In Process | $11,708,817 | $2,133,871 | - | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-26,552,738 | $-28,201,375 | $-29,060,212 | $-28,361,256 |
| Operating Activities | ||||
| Operating Cash Flow | $-26,552,738 | $-28,201,375 | $-29,060,212 | $-28,361,256 |
| Cash Flow From Continuing Operating Activities | $-26,552,738 | $-28,201,375 | $-29,060,212 | $-28,361,256 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-5,750,000 | $-5,000,000 | $0 | $0 |
| Cash Flow From Continuing Investing Activities | $-5,750,000 | $-5,000,000 | $0 | $0 |
| Net Other Investing Changes | $-5,750,000 | $-5,000,000 | - | - |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $32,303,148 | $13,803,684 | $13,798,183 | $0 |
| Financing Cash Flow | $33,303,148 | $9,972,327 | $13,829,450 | $0 |
| Cash Flow From Continuing Financing Activities | $33,303,148 | $9,972,327 | $13,829,450 | $0 |
| Net Other Financing Charges | $-300,000 | $-3,831,357 | - | - |
| Net Common Stock Issuance | $32,303,148 | $13,803,684 | $13,798,183 | $0 |
| Common Stock Issuance | $32,303,148 | $13,803,684 | $13,798,183 | $0 |
| Other | ||||
| Issuance Of Debt | $1,300,000 | $0 | - | - |
| Interest Paid Supplemental Data | $187,389 | $0 | - | - |
| End Cash Position | $4,252,290 | $3,251,880 | $26,480,928 | $41,711,690 |
| Beginning Cash Position | $3,251,880 | $26,480,928 | $41,711,690 | $70,072,946 |
| Changes In Cash | $1,000,410 | $-23,229,048 | $-15,230,762 | $-28,361,256 |
| Net Issuance Payments Of Debt | $1,300,000 | $0 | - | $0 |
| Net Short Term Debt Issuance | $1,300,000 | $0 | - | - |
| Short Term Debt Issuance | $1,300,000 | $0 | - | - |
| Change In Working Capital | $1,053,430 | $-1,685,001 | $-4,006,321 | $239,555 |
| Change In Other Working Capital | $1,063,429 | $72,035 | $394,732 | $-143,749 |
| Change In Other Current Liabilities | $-236,289 | $-218,380 | $-196,989 | $-177,237 |
| Change In Payables And Accrued Expense | $12,939,707 | $1,540,604 | $832,862 | $671,717 |
| Change In Accrued Expense | $4,173,226 | $-459,273 | $-929,094 | $783,434 |
| Change In Payable | $8,766,481 | $1,999,877 | $1,761,956 | $-111,717 |
| Change In Account Payable | $8,766,481 | $1,999,877 | $1,761,956 | $-111,717 |
| Change In Prepaid Assets | $-64,210 | $-945,389 | $-5,036,926 | $-111,176 |
| Change In Inventory | $-12,649,207 | $-2,133,871 | $0 | - |
| Other Non Cash Items | $26,600 | $284,176 | $102,000 | $378,204 |
| Stock Based Compensation | $10,836,291 | $11,839,678 | $6,616,705 | $3,905,954 |
| Deferred Tax | $1,056,960 | $576,000 | $576,000 | $576,000 |
| Deferred Income Tax | $1,056,960 | $576,000 | $576,000 | $576,000 |
| Depreciation Amortization Depletion | $214,250 | $209,611 | $194,316 | $179,677 |
| Depreciation And Amortization | $214,250 | $209,611 | $194,316 | $179,677 |
| Depreciation | $214,250 | $209,611 | $194,316 | $179,677 |
| Net Income From Continuing Operations | $-39,740,269 | $-39,425,839 | $-32,542,912 | $-33,640,646 |
| Proceeds From Stock Option Exercised | - | $0 | $31,267 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
| Change In Interest Payable | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-16